

Need a Speaker?

Interested In learning more about chemoresponse assays?

Precision has a 19-person faculty that includes key opinion leaders from around the country. For more information on setting up an event, contact Melissa Cottone at mcottone@ptilabs.com.

DID YOU KNOW?

Since introduction, over 5,000 ChemoFx tests have been performed in over 30 different types of cancers.

April 20-26 is National Medical Laboratory Professionals Week!

Precision would like to thank the many lab professionals in-house and around the country with whom we work. Please take a moment to recognize the important work that your local lab does every day!

WANT MORE INFO?



800-547-6165



info@ptilabs.com



What we do.

Precision Therapeutics is a diagnostics services company dedicated to providing physicians and patients with actionable clinical information to personalize cancer treatments. Precision's **ChemoFx[®]**, a proprietary live tumor cell-based platform, measures an individual patient's tumor **sensitivity and resistance** to a range of therapeutic alternatives under consideration by a physician.

Message from the CEO

Thank you for taking the time to read the first edition of our quarterly newsletter. At Precision, our mission is simple: to improve the treatment outcomes of patients living with cancer. To that end, we strive to provide a quality product and excellent customer service.

We also recognize the importance of clinical trials and remain committed to performing robust, well-designed studies for biomarker validation. Our partnerships with leading cancer organizations and renowned experts in the field allow us to pursue our goal of making Precision's clinical validation program second to none.

We hope that this newsletter will provide you with valuable information and open the lines of communication between Precision and our customers. We appreciate your support and look forward to an exciting year!

*Sean McDonald
President & CEO*

Reimbursement News

Reimbursement is a critical issue for physicians and patients. ChemoFx is covered by Medicare Part B and has been reimbursed by over 400 commercial insurance companies. We are also pleased to announce new contracts with leading organizations including SEIBA, NPPN, RMSCO and PCA. These new contracts expand our number of covered lives and offer faster payment for our test.

New Drugs Online

In addition to the existing 25+ anti-cancer agents available, several other drugs have recently passed our rigorous quality assurance procedures and are now offered for testing with ChemoFx:

- **Altretamine (Hexalen[®])** is used in patients with persistent or recurrent ovarian cancer.
- **Bleomycin (Blenoxane[®])** is indicated for testicular cancer and squamous cell carcinomas of the head & neck and the male and female reproductive systems.
- **Erlotinib (Tarceva[®])** is used in many settings, including advanced lung and pancreatic cancers. This is the first biologic agent offered for testing by Precision, with many more to come.

Gynecologic Studies Program

Precision appreciates the work of everyone involved in our clinical studies program. Below is an overview of our current gynecologic studies:

- The **ChemoFx Observational Study** examines the outcomes of patients with gynecologic malignancies who have had the ChemoFx Assay performed. To date, 152 patients have been enrolled from 14 facilities. Interested physicians are encouraged to contact us at observationalstudy@ptilabs.com.
- The **301 Trial** is a prospective study designed to determine the accuracy of ChemoFx prediction in patients with Stage II-IV recurrent ovarian, peritoneal, or fallopian tube cancer. 239 patients have been enrolled; accrual is expected to be complete in 2009.

Stay tuned...next month we will feature an overview of our **Breast Cancer Studies Program**, including an update on the release of new study results!

Precision Therapeutics[®]

The Science of Individualizing Cancer Therapy

www.precisiontherapeutics.com

Precision Therapeutics is a CLIA-certified clinical laboratory